Formulated nano-liposomes for reversal of cisplatin resistance in NSCLC with nucleus-targeting peptide
出版年份 2023 全文链接
标题
Formulated nano-liposomes for reversal of cisplatin resistance in NSCLC with nucleus-targeting peptide
作者
关键词
-
出版物
Nano Research
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2023-11-06
DOI
10.1007/s12274-023-6273-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer statistics, 2023
- (2023) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The use of nanoparticles for targeted drug delivery in non-small cell lung cancer
- (2023) Jessica E. Holder et al. Frontiers in Oncology
- Cell membrane coated-nanoparticles for cancer immunotherapy
- (2022) Yingping Zeng et al. Acta Pharmaceutica Sinica B
- A nucleus-targeting peptide antagonist towards EZH2 displays therapeutic efficacy for lung cancer
- (2022) Mei Jiang et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Engineering cancer cell membrane-camouflaged metal complex for efficient targeting therapy of breast cancer
- (2022) Xiaoying Li et al. JOURNAL OF NANOBIOTECHNOLOGY
- Non‐small cell lung cancer in China
- (2022) Peixin Chen et al. Cancer Communications
- Long non-coding RNA linc00665 inhibits CDKN1C expression by binding to EZH2 and affects cisplatin sensitivity of NSCLC cells
- (2021) Daolu Yang et al. Molecular Therapy-Nucleic Acids
- Prognostic significance of epigenetic regulatory gene expression in patients with non-small-cell lung cancer
- (2021) Zegui Tu et al. Aging-US
- Exploiting the acquired vulnerability of cisplatin-resistant tumors with a hypoxia-amplifying DNA repair–inhibiting (HYDRI) nanomedicine
- (2021) Jing Chen et al. Science Advances
- Myristoylation-mediated phase separation of EZH2 compartmentalizes STAT3 to promote lung cancer growth
- (2021) Jie Zhang et al. CANCER LETTERS
- Cell membrane–camouflaged liposomes for tumor cell–selective glycans engineering and imaging in vivo
- (2021) Zhengwei Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cisplatin resistance of NSCLC cells involves upregulation of visfatin through activation of its transcription and stabilization of mRNA
- (2021) Zihao Lu et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Histone modifications and their role in epigenetics of cancer
- (2021) Sumera Zaib et al. CURRENT MEDICINAL CHEMISTRY
- CBX2 and EZH2 cooperatively promote the growth and metastasis of lung adenocarcinoma
- (2021) Fei-Fei Hu et al. Molecular Therapy-Nucleic Acids
- A positive feedback loop formed by NGFR and FOXP3 contributes to the resistance of non-small cell lung cancer to icotinib
- (2020) Jun Huang et al. Translational Cancer Research
- Exosome-transmitted lncRNA UFC1 promotes non-small-cell lung cancer progression by EZH2-mediated epigenetic silencing of PTEN expression
- (2020) Xueyan Zang et al. Cell Death & Disease
- Association of the Epithelial–Mesenchymal Transition (EMT) with Cisplatin Resistance
- (2020) Milad Ashrafizadeh et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A novel PPARɣ ligand, PPZ023, overcomes radioresistance via ER stress and cell death in human non-small-cell lung cancer cells
- (2020) Tae Woo Kim et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- Advances in Oligonucleotide Aptamers for NSCLC Targeting
- (2020) Deborah Rotoli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Epigenetic therapy for ovarian cancer: promise and progress
- (2019) Sara Moufarrij et al. Clinical Epigenetics
- Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
- (2019) Edward B. Garon et al. JOURNAL OF CLINICAL ONCOLOGY
- LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC
- (2019) Xinyin Liu et al. Molecular Therapy-Nucleic Acids
- New Insights into Mechanisms of Cisplatin Resistance: From Tumor Cell to Microenvironment
- (2019) Shang-Hung Chen et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Aberrant N-cadherin expression in cancer
- (2019) Zhan-Qi Cao et al. BIOMEDICINE & PHARMACOTHERAPY
- pH-Sensitive N,N-Dimethylalkane-1-amine N-Oxides in DNA Delivery: From Structure to Transfection Efficiency
- (2019) Gilda Liskayová et al. LANGMUIR
- EZH2 Contributes To Cisplatin Resistance In Breast Cancer By Epigenetically Suppressing miR-381 Expression
- (2019) Dongwei Dou et al. OncoTargets and Therapy
- Frontline immunotherapy for NSCLC: alone or not alone?
- (2018) Cesare Gridelli et al. Nature Reviews Clinical Oncology
- The efficiency of lipid nanoparticles with an original cationic lipid as a siRNA delivery system for macrophages and dendritic cells
- (2018) Yasunori Uemura et al. PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
- (2018) Ugo Testa et al. Cancers
- P2-001The functional role of NGFR in regulating chemosensitivity in nasopharyngeal carcinoma
- (2018) Wei Gao et al. ANNALS OF ONCOLOGY
- A central role for cadherin signaling in cancer
- (2017) Antonis Kourtidis et al. EXPERIMENTAL CELL RESEARCH
- Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
- (2017) Meng Zhang et al. Cancer Biology & Medicine
- Liposomes Coated with Isolated Macrophage Membrane Can Target Lung Metastasis of Breast Cancer
- (2016) Haiqiang Cao et al. ACS Nano
- Targeting EZH2 in cancer
- (2016) Kimberly H Kim et al. NATURE MEDICINE
- Cisplatin resistance and opportunities for precision medicine
- (2016) Lauren Amable PHARMACOLOGICAL RESEARCH
- Prognostic Significance of EZH2 Expression in Non-Small Cell Lung Cancer: A Meta-analysis
- (2016) Xinhua Wang et al. Scientific Reports
- siRNA Silencing EZH2 Reverses Cisplatin-resistance of Human Non-small Cell Lung and Gastric Cancer Cells
- (2015) Wen Zhou et al. Asian Pacific Journal of Cancer Prevention
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy
- (2014) Chunhua Xu et al. LUNG CANCER
- Systems biology of cisplatin resistance: past, present and future
- (2014) L Galluzzi et al. Cell Death & Disease
- Nanomedicine therapeutic approaches to overcome cancer drug resistance
- (2013) Janet L. Markman et al. ADVANCED DRUG DELIVERY REVIEWS
- Prognostic Significance of Twist and N-Cadherin Expression in NSCLC
- (2013) Linping Hui et al. PLoS One
- Nanoparticle-based combination therapy toward overcoming drug resistance in cancer
- (2012) Che-Ming Jack Hu et al. BIOCHEMICAL PHARMACOLOGY
- Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC)
- (2012) Corey J. Langer et al. CANCER TREATMENT REVIEWS
- Cancer Epigenetics: From Mechanism to Therapy
- (2012) Mark A. Dawson et al. CELL
- The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications
- (2012) Mark P Chao et al. CURRENT OPINION IN IMMUNOLOGY
- Genetic heterogeneity and cancer drug resistance
- (2012) Nicholas C Turner et al. LANCET ONCOLOGY
- Histone methylation: a dynamic mark in health, disease and inheritance
- (2012) Eric L. Greer et al. NATURE REVIEWS GENETICS
- Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer
- (2011) Huqun et al. CANCER
- Vimentin in cancer and its potential as a molecular target for cancer therapy
- (2011) Arun Satelli et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Cell signaling molecules as drug targets in lung cancer: an overview
- (2011) Tapan K Mukherjee et al. CURRENT OPINION IN PULMONARY MEDICINE
- Ovarian Cancer Stem Cell-Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2
- (2011) S. Rizzo et al. MOLECULAR CANCER THERAPEUTICS
- The Polycomb complex PRC2 and its mark in life
- (2011) Raphaël Margueron et al. NATURE
- Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo
- (2010) Sha Hu et al. CANCER BIOLOGY & THERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search